O	0	14	Administration
O	15	17	of
B-intervention	18	30	subcutaneous
I-intervention	31	39	buffered
I-intervention	40	49	lidocaine
O	50	55	prior
O	56	58	to
O	59	65	breast
O	66	84	lymphoscintigraphy
O	85	92	reduces
B-condition	93	97	pain
O	98	105	without
O	106	116	decreasing
O	117	122	lymph
O	123	127	node
O	128	141	visualization
O	141	142	.

O	143	149	Breast
O	150	168	lymphoscintigraphy
O	169	174	using
O	175	176	(
O	176	179	99m
O	179	180	)
O	180	182	Tc
O	182	183	-
O	183	189	sulfur
O	190	197	colloid
O	198	199	(
O	199	200	(
O	200	203	99m
O	203	204	)
O	204	206	Tc
O	206	207	-
O	207	209	SC
O	209	210	)
O	211	213	is
O	214	218	well
O	219	230	established
O	231	233	in
O	234	242	clinical
O	243	251	practice
O	252	255	for
O	256	263	staging
O	264	272	patients
O	273	277	with
O	278	284	breast
O	285	294	carcinoma
O	294	295	.

O	296	302	Nearly
O	303	306	all
O	307	315	patients
O	316	322	report
O	323	329	having
O	330	334	pain
O	335	341	during
O	342	345	the
O	346	355	procedure
O	355	356	.

O	357	364	However
O	364	365	,
O	366	376	techniques
O	377	381	used
O	382	384	to
O	385	393	minimize
O	394	398	pain
O	399	405	during
O	406	412	breast
O	413	431	lymphoscintigraphy
O	432	435	are
O	436	442	highly
O	443	451	variable
O	452	458	across
O	459	471	institutions
O	471	472	.

O	473	476	Our
O	477	482	study
O	483	486	was
O	487	489	to
O	490	499	determine
O	500	507	whether
O	508	521	anesthetizing
O	522	525	the
O	526	530	skin
O	531	535	with
O	536	542	sodium
O	543	560	bicarbonatehether
O	560	561	-
O	561	569	buffered
O	570	579	lidocaine
O	580	586	before
O	587	597	performing
O	598	604	breast
O	605	623	lymphoscintigraphy
O	624	631	reduced
O	632	635	the
O	636	640	pain
O	641	652	experienced
O	653	655	by
O	656	659	the
O	660	668	patients
O	668	669	.

O	670	673	The
O	674	680	second
O	681	690	objective
O	691	693	of
O	694	698	this
O	699	704	study
O	705	708	was
O	709	711	to
O	712	720	evaluate
O	721	728	whether
O	729	742	anesthetizing
O	743	746	the
O	747	751	skin
O	752	756	with
O	757	765	buffered
O	766	775	lidocaine
O	776	783	changed
O	784	797	visualization
O	798	800	of
O	801	806	lymph
O	807	812	nodes
O	812	813	.

O	814	818	This
O	819	830	prospective
O	830	831	,
O	832	839	patient
O	839	840	-
O	840	846	masked
O	847	850	and
O	851	861	randomized
O	862	867	study
O	868	876	involved
O	877	887	performing
O	888	894	breast
O	895	913	lymphoscintigraphy
O	914	916	in
O	917	918	a
B-control	919	926	control
I-control	927	932	group
O	933	936	and
O	937	949	experimental
O	950	955	group
O	956	958	of
O	959	965	female
O	966	972	breast
O	973	979	cancer
O	980	988	patients
O	988	989	.

O	990	993	The
O	994	1001	control
O	1002	1007	group
O	1008	1011	did
O	1012	1015	not
O	1016	1023	receive
O	1024	1028	skin
O	1029	1039	anesthetic
O	1040	1046	before
O	1047	1048	(
O	1048	1051	99m
O	1051	1052	)
O	1052	1054	Tc
O	1054	1055	-
O	1055	1057	SC
O	1058	1068	injections
O	1068	1069	,
O	1070	1077	whereas
O	1078	1081	the
O	1082	1094	experimental
O	1095	1100	group
O	1101	1106	first
O	1107	1116	underwent
O	1117	1121	skin
O	1122	1132	anesthesia
O	1133	1137	with
O	1138	1140	an
O	1141	1150	injection
O	1151	1153	of
O	1154	1155	2
O	1155	1156	%
O	1157	1163	sodium
O	1164	1175	bicarbonate
O	1175	1176	-
O	1176	1184	buffered
O	1185	1194	lidocaine
O	1194	1195	.

O	1196	1199	All
O	1200	1208	patients
O	1209	1213	were
O	1214	1219	asked
O	1220	1222	to
O	1223	1227	rate
O	1228	1233	their
O	1234	1238	pain
O	1239	1245	levels
O	1245	1246	,
O	1247	1252	using
O	1253	1256	the
O	1257	1265	National
O	1266	1276	Institutes
O	1277	1279	of
O	1280	1286	Health
O	1287	1291	pain
O	1292	1297	scale
O	1297	1298	,
O	1299	1305	before
O	1306	1309	the
O	1310	1319	procedure
O	1320	1323	and
O	1324	1335	immediately
O	1336	1341	after
O	1342	1345	the
O	1346	1356	injections
O	1356	1357	.

O	1358	1361	The
O	1362	1368	change
O	1369	1371	in
O	1372	1376	pain
O	1377	1381	from
O	1382	1390	baseline
O	1391	1394	was
O	1395	1403	compared
O	1404	1411	between
O	1412	1415	the
O	1416	1417	2
O	1418	1424	groups
O	1424	1425	.

O	1426	1431	After
O	1432	1435	the
O	1436	1446	injections
O	1446	1447	,
O	1448	1461	scintigraphic
O	1462	1469	imaging
O	1470	1472	of
O	1473	1476	the
O	1477	1483	axilla
O	1484	1487	was
O	1488	1497	performed
O	1497	1498	,
O	1499	1502	and
O	1503	1506	the
O	1507	1513	number
O	1514	1516	of
O	1517	1525	axillary
O	1526	1531	lymph
O	1532	1537	nodes
O	1538	1548	visualized
O	1549	1552	was
O	1553	1561	recorded
O	1561	1562	.

O	1563	1565	No
O	1566	1577	significant
O	1578	1588	difference
O	1589	1592	was
O	1593	1598	found
O	1599	1601	in
B-outcome	1602	1615	preprocedural
I-outcome	1616	1624	baseline
I-outcome	1625	1629	pain
O	1630	1634	from
O	1635	1638	the
O	1639	1646	control
O	1647	1652	group
O	1652	1653	,
O	1654	1662	compared
O	1663	1667	with
O	1668	1671	the
O	1672	1684	experimental
O	1685	1690	group
O	1690	1691	.

O	1692	1697	There
O	1698	1701	was
O	1702	1703	a
O	1704	1717	statistically
O	1718	1729	significant
O	1730	1740	difference
O	1741	1743	in
O	1744	1747	the
O	1748	1756	increase
O	1757	1759	in
B-outcome	1760	1764	pain
I-outcome	1765	1776	experienced
I-outcome	1777	1783	during
I-outcome	1784	1787	the
I-outcome	1788	1797	procedure
O	1798	1805	between
O	1806	1809	the
O	1810	1817	control
O	1818	1823	group
O	1824	1827	and
O	1828	1831	the
O	1832	1844	experimental
O	1845	1850	group
O	1851	1852	(
O	1852	1853	P
O	1854	1855	=
O	1856	1857	0
O	1857	1858	.
O	1858	1861	009
O	1861	1862	)
O	1862	1863	.

O	1864	1869	There
O	1870	1873	was
O	1874	1876	no
O	1877	1888	significant
O	1889	1899	difference
O	1900	1902	in
O	1903	1906	the
B-outcome	1907	1916	detection
I-outcome	1917	1919	of
I-outcome	1920	1925	lymph
I-outcome	1926	1931	nodes
O	1932	1939	between
O	1940	1943	the
O	1944	1951	control
O	1952	1955	and
O	1956	1968	experimental
O	1969	1975	groups
O	1976	1977	(
O	1977	1978	P
O	1979	1980	=
O	1981	1982	0
O	1982	1983	.
O	1983	1985	56
O	1985	1986	)
O	1986	1987	.

O	1988	1991	The
O	1992	1999	results
O	2000	2004	from
O	2005	2008	our
O	2009	2014	study
O	2015	2023	indicate
O	2024	2028	that
O	2029	2038	injecting
O	2039	2051	subcutaneous
O	2052	2060	buffered
O	2061	2070	lidocaine
O	2071	2077	before
O	2078	2089	intradermal
O	2090	2099	injection
O	2100	2102	of
O	2103	2104	(
O	2104	2107	99m
O	2107	2108	)
O	2108	2110	Tc
O	2110	2111	-
O	2111	2113	SC
O	2114	2117	for
O	2118	2124	breast
O	2125	2143	lymphoscintigraphy
O	2144	2157	significantly
O	2158	2167	decreases
O	2168	2175	patient
O	2176	2180	pain
O	2181	2188	without
O	2189	2200	interfering
O	2201	2205	with
O	2206	2211	lymph
O	2212	2216	node
O	2217	2230	visualization
O	2230	2231	.
